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Abstract
Background: The goal of this perform a systematic review on the outcomes of bone marrow aspirate concentrate
(BMAC) for the treatment of chondral defects and osteoarthritis (OA) of the talus.
Results: The systematic search performed identified 47 studies after duplicates were removed. After inclusion
criteria were applied four studies were considered for insightful analysis for the treatment of focal chondral defects
in the foot and ankle with the use of BMAC. Three studies were retrospective and one study was prospective in
nature. One study was a comparative cohort study and three studies were case series.
Conclusions: This review denotes that there exists an overwhelming paucity of long-term data and high-level evidence
supporting BMAC for the treatment of chondral defects. Nonetheless, the evidence available showed varying degrees of
beneficial results of BMAC for the treatment of ankle cartilage defects. The limited literature presented in this review
demonstrates the need for more advanced, comparative studies to further investigate the efficacy, safety and techniques
for BMAC in the treatment of OLTs. The authors recommend that BMAC therapy should be performed with careful
consideration until the application and target population for this treatment are established.
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Background
Osteochondral lesions of the talus (OLTs) have become
increasingly diagnosed and treated as advanced imaging
technologies continue to improve the ability to detect
cartilage defects (Potter et al. 2008; Verhagen et al. 2005;
Leumann et al. 2011). In fact, some reports suggest that
up to 50 % of acute ankle sprains and fractures may have
associated OLTs (Savage-Elliott et al. 2014; Saxena and
Eakin 2007). Common symptoms of OLTs include in-
creased pain, stiffness, and functional limitations includ-
ing decreases in activity level (Savage-Elliott et al. 2014).
Biological adjuncts such as bone marrow aspirate con-
centrate (BMAC) may be useful in increasing the lon-
gevity of cartilage repair procedures of the talus. Bone
marrow aspirate consists of both mesenchymal stem
cells (MSCs) and hematopoietic stem cells. Bone marrow
aspirate concentrate has been theorized to facilitate
regeneration of tissue, enhancing the quality of cartilage
repair by increasing aggrecan content and tissue firm-
ness (Sampson et al. 2013). As a result, BMAC promotes
a potentially healthy environment for hyaline cartilage
growth and repair, while minimizing the formation of
fibrocartilage (Fortier et al. 2011; Smyth et al. 2012;
Kennedy and Murawski 2011).
These concepts have now been studied in animal
models, which have initially shown promising results
and a limited complication profile in regards to BMAC
(Fortier et al. 2010; Saw et al. 2009). The addition of
BMAC to bone marrow stimulation (BMS) techniques
significantly improved cartilage healing compared to
BMS alone. Specifically, cartilage defects healed with a
higher content of hyaline cartilage (collagen type II),
more glycosaminoglycan, and better overall histological
organization (Saw et al. 2009; Fortier et al. 2010). These
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results have led to the investigation of BMAC for the
treatment of OLTs in human patients (Smyth et al.
2012). Moreover, BMAC is currently one of the few,
United States Food and Drug Administration (FDA)-ap-
proved forms of delivering stem cells intraoperatively
(McCright et al. 2009).
The overall evidence for treating chondral diseases
using BMAC is limited and highly heterogeneous with
respect to indications, timing, and results. However, out-
comes following the use of BMAC for the treatment of
OLTs have been previously documented (Hannon et al.
2016; Giannini et al. 2009; Kennedy and Murawski
2011); (Giannini et al. 2013). The purpose of this study
was to systematically review the literature regarding
indications, outcomes, complications and safety profile
following the use of BMAC for the treatment of OLTs.
Methods
Article identification and selection
This study was conducted in accordance with the 2009
Preferred Reporting Items for Systematic Review and
Meta-Analysis (PRISMA) statement (Moher et al. 2009).
A systematic review of the literature regarding the exist-
ing evidence for outcomes for the treatment of chondral
defects and osteoarthritis of the talus with BMAC was
performed using the Cochrane Database of Systematic
Reviews, the Cochrane Central Register of Controlled Tri-
als, PubMed (1980–2016), and MEDLINE (1980–2016).
The queries were performed in May 2016.
The literature search strategy included the following:
Search Term 1: (“bone marrow”[MeSH Terms] OR
“bone marrow”[All Fields]) AND (“aspirate”[All Fields]
OR “concentrate”[All Fields]) AND (“ankle”[All Fields]
OR “ankle”[MeSH Terms] OR “foot”[All Fields] OR
“foot”[MeSH Terms])
Search Term 2: bone[All fields] AND marrow[All fields]
AND aspirate[All fields] AND (“ankle”[Mesh Terms] OR
(“ankle”[All fields] AND “joint”[All fields]) OR “ankle
joint” [All fields])
Inclusion criteria were as follows: BMAC for the treat-
ment of cartilage defects of the ankle, English language, hu-
man studies with a follow-up greater than 12 months.
Exclusion criteria consisted of cadaveric studies, animal
studies, basic science articles, editorials articles, surveys,
special topics, letters to the editor, personal correspond-
ence, studies that did not include the talus or BMAC for
treatment, of other pathologies not related to the cartilage.
Two investigators (initials blinded for review) inde-
pendently reviewed the abstracts from all identified arti-
cles. Full-text articles were obtained for review if
necessary to allow further assessment of inclusion and
exclusion criteria. Additionally, all references from the
included studies were reviewed and reconciled to verify
that no relevant articles were missing from the system-
atic review.
Data collection
The level of evidence of the studies was assigned according
to the classification as specified by (Wright et al. 2003). The
following information was extracted and recorded from the
included studies: patient demographics, follow-up, and ob-
jective and subjective outcomes. For continuous variables
(age, timing, follow-up, outcome scores), the mean and
range were collected if reported. Data were recorded into
a custom spreadsheet (Microsoft Corp) using a modified
information extraction table (Harris et al. 2014).
Literature quality evaluation
A modified version of the Coleman methodology score
(mCMS) to assess the quality of methodology in each
study was utilized (Kon et al. 2009). The two part
mCMS grades cartilage-related studies based on ten cri-
teria; Part A: study size, mean follow-up, number of dif-
ferent surgical procedures, type of study, description of
surgical procedure, postoperative rehabilitation, inclu-
sion subjects’ MRI outcome and inclusion subjects’
histological outcome; Part B: outcome criteria, pro-
cedure for assessing clinical outcomes and description
of subject selection process. The maximum score of
the mCMS is 100, which indicates that a study largely
avoids chance, biases and confounding factors. Two
authors (initials blinded for review) independently




The systematic search performed using the previously
mentioned keywords identified 47 studies after dupli-
cates were removed. Of these, 37 were basic science
studies, cadaveric studies, or studies unrelated to our
topic, leaving 10 articles. Of the remaining studies, 3
reported on alternate indications and use of BMAC such
as fracture healing, 2 were case reports and 1 study pub-
lished on the same patient cohort published in a previ-
ous study. After applying all exclusion criteria, 4 studies
for the treatment of focal chondral defects in the ankle
with the use of BMAC were considered. Three studies
were retrospective (Giannini et al. 2013; Giannini et al.
2009; Kennedy and Murawski 2011) and one study
(Hannon et al. 2016) was prospective in nature. One
study was a comparative cohort study (Hannon et al.
2016) and three studies were case series (Giannini et al.
2013; Giannini et al. 2009; Kennedy and Murawski
2011). There was considerable heterogeneity of indica-
tions, subjective outcomes measures, and objective
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data (e.g. MRI, second look arthroscopy) among the
included studies. Figure 1 demonstrates a PRISMA
flowchart of the selection criteria of the studies found
with our search.
Demographics
The review included a total of 184 patients with a mean
age of 29.5 years in the included studies. Average follow-
up of the included studies was 34.3 months (range, 24 to
77 months). Lesion location was also well distributed
among studies, with a higher incidence of medial talar
dome lesions (n = 146) compared to lateral talar dome
lesions (n = 56). Two studies (Hannon et al. 2016;
Kennedy and Murawski 2011) further specified lesion
location with the 9-zone anatomic localization scheme
on MRI proposed by (Elias et al. 2007), which can be
found in Table 1.
Indications
All included studies utilized BMAC injection as an
adjunct for treatment of OLTs. However, procedures
between studies were variable with one study per-
forming only microfracture both with and without
BMAC augmentation,(Hannon et al. 2016) one study
performing only OAT with BMAC,(Kennedy and
Murawski 2011) and two studies performing arthroscopic
debridement with BMAC placement with one of two scaf-
folds (Giannini et al. 2013; Giannini et al. 2009). The
study, in which OAT was performed, lesion size was at
least 6 mm in diameter (Kennedy and Murawski 2011). In
the studies by (Giannini et al. 2009; Giannini et al. 2013)
scaffolds were used for large, chronic Type II lesions
(>1.5 cm2 area, < 5 mm deep).
BMAC extraction and processing
The quantity of bone marrow aspirate extracted was
consistent in all studies (60 mL) from the anterior iliac
crest in two studies (Hannon et al. 2016; Kennedy and
Murawski 2011) and from the posterior iliac crest in the
remaining two studies (Giannini et al. 2013; Giannini et
al. 2009). Processing systems utilized were heteroge-
neous: (Hannon et al. 2016) utilized an Arteriocyte
Magellan Autologous Platelet Separator System (obtaining
3 ml of BMAC). Giannini (Giannini et al. 2009; Giannini
et al. 2013) utilized the Harvest Tech Smart PReP to
obtain 6 mL of BMAC. Finally, the centrifuge used by
Kennedy (2011) was not reported in their study
although they obtained 4 mL as a result of the BMA
processing (Table 2).
Fig. 1 PRISMA flowchart of the included studies
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Patient reported outcomes
Post-procedure imaging, second-look arthroscopy, and
quality of the repair tissue
Two studies performed postoperative MRIs at a mini-
mum 24 months follow-up to assess the quality of the
repair (Hannon et al. 2016; Giannini et al. 2009); (Hannon
et al. 2016) utilized the magnetic resonance observation of
cartilage repair tissue (MOCART) (Marlovits et al. 2006)
score and found significantly higher scores in the BMS
with BMAC group compared to BMS alone. Specifically,
they reported significantly improved defect filling, border
repair integration and surface tissue repair along with far
less evidence of fissuring and fibrillation in OLTs treated
with BMAC (Hannon et al. 2016). At 2 year follow-up,
(Giannini et al. 2009) reported that all patients showed
evidence of restored cartilage layer at the OLTs defect site
on MRI. Additionally, (Giannini et al. 2009) performed
second-look arthroscopy in 5 patients at a mean
13 months. Three of these patients were asymptomatic
and the other 2 patients reported symptoms of continued
pain. Second-look arthroscopy showed evidence of chon-
dral hypertrophy in the 2 symptomatic patients, but all
patients showed evidence of complete and healthy cartil-
age integration. Histological and immunohistochemical
analysis of three patient biopsy samples collected at
12 month revealed various degrees of hyaline cartilage ref-
ormation with visible chondrogenic growth, increased
hyaline cartilage and proteoglycan content (Giannini et al.
2009). Giannini et al. also utilized MRI T2/MOCAT score
in 20 patients from their 49 patient four year follow up
cohort. They found no significant relationship between
MOCART score parameters and patient outcomes at
48 months (Giannini et al. 2013).
Return to activity
Giannini (2009) reported that 94 % of patients returned
to low impact sports activity at a mean 4.4 months and
77 % of patients returned to high impact sports activity
at a mean 11.3 months. The same authors reported that
73 % of the 36 patients playing sports before surgery
were able to return to sports in a different study
(Giannini et al. 2013). They also reported that 22 %
of these 36 patients were able to return to sport, but
at a lower level than before surgery (Giannini et al.
2013) Kennedy et al.(2011) reported that 95 % of
patients who had undergone OAT with BMAC aug-
mentation returned to their pre-symptom level of
sporting activity at a mean 13 weeks.
Safety
There were 8 complications reported in the included
studies. The most common complication was donor site
knee pain in 3 patients in which the lateral femoral condyle
was used as the graft site (Kennedy and Murawski 2011).
There were two reports of subchondral cyst formation, one
at the graft harvest site (Kennedy and Murawski 2011) and
one in the OLTs lesion (Hannon et al. 2016) In patients
who received BMAC in addition to BMS, 2 superficial
peroneal nerve dysesthesias were reported (Hannon et al.
2016). Lastly, there was 1 patient who developed a
superficial infection at one of the arthroscopic portal
sites (Giannini et al. 2013).
Literature methodological quality assessment
The mean score of the included studies was 57 out of 100
points using the Kon-Verdonk modified Coleman meth-
odology score (Kon et al. 2009). The mean score was 64
points for the Hannon et al. (2016) study, 62 points for
both of the Giannini (2013; Giannini et al. 2009) studies
and 40 points for the Kennedy et al.(2011) study.
Discussion
The most important finding of this review was that there
was a scarcity of information in the literature on the use
of BMAC for the treatment of OLTs with highly hetero-
geneous indications, associated procedures and outcome
measurements. However, the reviewed studies showed
varying degrees of beneficial outcomes for the treatment
of moderately sized chondral defects with no major
complications reported. While the three studies included
in this review were of moderate to high quality, as deter-
mined by the mCMS, only one study was prospective
and used a control group (Hannon et al. 2016). Despite
increased use, development, and popularity of BMAC,
additional comparative studies are certainly necessary to
provide additional support for its efficacy in the treat-
ment of OLTs.
Favorable short- and medium-term outcomes for the
treatment of focal cartilage defects and osteoarthritis
have been reported in other joints, such as the knee
(Bhatia et al. 2015). However, the indications, delivery
method, and composition of BMAC have been heteroge-
neous. In the present studies (Giannini et al. 2009;
Kennedy and Murawski 2011; Hannon et al. 2016; Gian-
nini et al. 2013). BMAC has been used in conjunction
with either synthetic scaffolds, OAT or BMS and
resulted in good short-term clinical outcomes. BMAC
has also been delivered with a porcine collagen matrix
and hyaluronic acid membranes (Buda et al. 2013). Fur-
thermore, three studies (Giannini et al. 2009; Kennedy
and Murawski 2011; Giannini et al. 2013) reported that
the vast majority of patients were able to successfully
return to athletic activity. Certainly, further studies are
warranted to determine the optimal delivery and com-
position of BMAC.
Follow-up MRI in three of the included studies
(Giannini et al. 2009; Hannon et al. 2016; Giannini et al.
2013) supported good cartilage defect filling. Hannon et al.
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(Hannon et al. 2016) reported significantly greater MRI
findings among patients treated with BMAC and BMS
compared to patients treated with BMS alone. The findings
reported by Hannon et al. are similar to those reported by
Fortier et al.(2010) In a comparative study of microfracture
with or without BMAC augmentation for the treatment of
full thickness cartilage defects in an equine knee model,
Fortier et al.(2010) reported improved defect filling, integra-
tion of repair tissue, collagen orientation and increased gly-
cosaminoglycan and type II collagen content in the BMAC
group. Only one study (Giannini et al. 2009) in this
review performed second-look arthroscopy. All 5
patients showed evidence of complete and healthy
cartilage integration at a mean 13 months; however,
evidence of hypertrophic chondral growth in 2 symp-
tomatic patients raises particular concern.
In the reviewed studies, few complications were
reported, and no complications were attributed to the
BMAC injection itself. Only superficial infection at a
portal site were reported in the study utilizing scaffold
supported BMAC (Giannini et al. 2009). Following
BMAC soaked OAT, three patients suffered from donor
site-morbidity related pain and one MRI at 28 months
follow-up revealed cyst formation beneath the graft site
(Kennedy and Murawski 2011). Two patients com-
plained of superficial peroneal nerve dysesthesia after
microfracture and BMAC treatment (Hannon et al.
2016). There were no reports of neoplasia or excessive
bone formation. However, Giannini et al.(2009) did
report two symptomatic patients with evidence chondral
hypertrophy at second-look arthroscopy. Overall, bone
marrow aspirate appears to be a safe biologic adjunct.
Clanton et al.(2014) reported short-term results of 7
patients (mean age: 43.7 years) at a mean follow-up of
8.4 months (range: 6.3 to 12.6) following arthroscopic
treatment of OLTs with microfracture and a mixture of
cartilage extracellular matrix augmented with BMAC.
Mean Foot and Ankle Disability Index (FADI) Activities
and Daily Living (Mesfar and Shirazi-Adl 2008) subscale
scores improved from 64 (range: 39–89) preoperatively
to 83 (range: 62–100) at follow-up. Mean FADI sports
subscale improved from 29 (range: 0–47) to 53 (range:
22–100) postoperatively. Mean FADI total score im-
proved from 56 (range: 33–79) to 76 (range: 52–100) at
follow-up. This study was excluded from our systematic
review due to the follow-up time of less than 12 months.
However, these preliminary outcomes are important for es-
tablishing BMAC as a viable technique for OLT treatment.
The authors recognize some limitations of this system-
atic review. In the evaluated studies, BMAC was used to
augment a variety of surgical techniques for treatment of
OLTs. Therefore, the results of this study do not demon-
strate the efficacy and safety of BMAC as an isolated
therapy. The heterogeneity in the presentation of results
diminishes the ability to compare subjective and object-
ive outcomes across studies. Similarly, there was limited
consistency in the quantitative description of osteochon-
dral lesion size. The lack of control groups in the pre-
sented studies decreases the ability to evaluate relative
efficacy of the procedures. Furthermore, the relatively
short-term results of the included studies are not repre-
sentative of the long-term implications of BMAC treat-
ment for OLTs and this should be considered when
interpreting this review. Lastly, inherent to any system-
atic review, there is the possibility that not all relevant
articles were identified through the used search terms
and literature review.
Conclusion
This review denotes that there exists an overwhelming
paucity of long-term data and high-level evidence sup-
porting this treatment method. Nonetheless, the evi-
dence available showed varying degrees of beneficial
results of BMAC for the treatment of ankle cartilage
defects. The limited literature presented in this review
demonstrates the need for more advanced, comparative
studies to further investigate the efficacy, safety and
techniques for BMAC in the treatment of OLTs. The au-
thors recommend that BMAC therapy should be per-
formed with careful consideration until the application
and target population for this treatment are established.
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